



BLUE JET HEALTHCARE LIMITED

REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

T : 022- 41840550 / 40037603

F : +91 22 27814204

E : sales@bluejethealthcare.com

CIN NO. : L99999MH1968PLC014154

July 22, 2025

To,

The Manager Listing Department BSE Limited Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
---	---

Sub.: Outcome of Board Meeting held today i.e, Tuesday, July 22, 2025.

Dear Sir / Ma'am,

In terms of Regulation 30 and Regulation 33 read with Schedule III and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Board of Directors of the Company at their meeting held today viz. Tuesday, July 22, 2025, *inter-alia*, has approved the following: -

- Unaudited Standalone Financial Results of the Company for the first quarter ended June 30, 2025. A signed copy of the Unaudited Standalone Financial Results along with the Limited Review Report thereon is enclosed herewith.

The meeting commenced at 11:58 A.M. and concluded at 12:25 P.M.

Kindly take the same on your record.

Thanking you,
Yours faithfully,

For Blue Jet Healthcare Limited

Ms. Sweta Poddar
Company Secretary & Compliance Officer
Mem. No. F12287

Unit I
3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, Tel.: 91 251 2280283 Fax : +91 251 2280567
Unit II
Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambarnath (W) 421501. Tel. : +91 8956363877/8956363878
Unit III
K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, Tel.: + 91 22 2207 5307 / 6192 / 1691 Fax : +91 22 2207 0294

Email : info@bluejethealthcare.com / Website : www.bluejethealthcare.com

kkc & associates llp

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Independent Auditor's Review Report on unaudited financial results for the quarter ended 30 June 2025 of Blue Jet Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Blue Jet Healthcare Limited

Introduction

1. We have reviewed the accompanying statement of unaudited financial results of Blue Jet Healthcare Limited ('the Company') for the quarter ended 30 June 2025 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



kkc & associates llp

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Other Matter

5. Attention is drawn to the fact that the figures for the quarter ended 31 March 2025 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

For **KKC & Associates LLP**

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Firm Registration Number: 105146W/W100621



Kamlesh R Jagetia

Partner

ICAI Membership No: 139585

UDIN: 25139585BMOWBX9452



Place: Navi Mumbai

Date: 22 July 2025

BLUE JET HEALTHCARE LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS ENDED 30-06-2025

₹ in million

Particulars	Three Months Ended			Year Ended
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	(Unaudited)	(Audited) (Refer Note 3)	(Unaudited)	(Audited)
1 Revenue from Operations	3,547.58	3,404.45	1,628.99	10,299.85
2 Other Income	82.54	122.25	87.15	462.56
3 Total Income (1+2)	3,630.12	3,526.70	1,716.14	10,762.41
4 Expenses				
Cost of Materials Consumed	1,078.90	1,634.81	908.95	5,402.45
Changes [Decrease /(Increase)] in Inventories of Finished goods and Work-in-Progress	750.07	(100.08)	(170.81)	(790.24)
Employee Benefits Expense	174.26	159.92	147.81	609.97
Finance Costs	6.90	0.34	0.27	0.98
Depreciation and Amortisation Expense	56.98	49.47	34.82	177.89
Other Expenses	334.41	310.12	300.41	1,300.37
Total Expenses	2,401.52	2,054.58	1,221.45	6,701.42
5 Profit before Tax (3-4)	1,228.60	1,472.12	494.69	4,060.99
6 Tax Expense:				
Current Tax	298.00	365.00	97.50	965.00
Short/ (Excess) Tax Provision related to prior years	-	2.75	-	2.75
Deferred Tax	18.90	3.42	19.42	41.21
Total Tax Expense	316.90	371.17	116.92	1,008.96
7 Profit for the period/ year (5-6)	911.70	1,100.95	377.77	3,052.03
8 Other Comprehensive Income				
(i) Items that will not be reclassified to profit or loss	-	0.42	-	0.42
(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	(0.10)	-	(0.10)
Other Comprehensive Income for the period/ year	-	0.32	-	0.32
9 Total Comprehensive Income for the period/ year (7 + 8)	911.70	1,101.27	377.77	3,052.35
10 Paid-up Equity Share Capital (Face Value ₹ 2 per share)	346.93	346.93	346.93	346.93
11 Other Equity				10,984.18
12 Earnings per Share (EPS) of Face value ₹ 2/- each*				
(a) Basic - (₹)	5.26	6.35	2.18	17.59
(b) Diluted - (₹)	5.26	6.35	2.18	17.59

*EPS are not annualised for interim periods

Notes:

- The above financial results of the Company for the three months ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on July 22, 2025. Further, the above financial results have been reviewed by the Statutory Auditor of the Company.
- The company is engaged in manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products.
- The results for the three months ended March 31, 2025 are balancing figure between the audited financial statements for the financial year ended March 31, 2025 and published unaudited results for nine months ended December 31, 2024.
- The Company does not have any subsidiaries, associates, or joint ventures as on June 30, 2025. Consequently, the preparation of consolidated financial statements is not applicable.

Navi Mumbai
Date: July 22, 2025



For and on behalf of Board of Directors

Shiven Arora
Shiven Arora
Managing Director